Company Overview and News
OSLO, June 7 (Reuters) - * Norwegian shares traded up on Thursday * Oslo’s benchmark index rose 0.98 pct, or 8.63 points, to 891.61 points and was up by 8.42 pct year-to-date * The broader Oslo All Share Index was up 0.98 percent * Brent crude futures, a trigger for the oil heavy Oslo Bourse, rose $1.17 to $76.53 a barrel * Oil rises as reality dawns over Venezuela’s export crisis * Among the biggest firms on the Oslo Bourse, Equinor rose 1.
YRAIF QEC YARIY XXLLY QTEYF
OSLO, June 5 (Reuters) - * Norwegian shares traded down on Tuesday * Oslo’s benchmark index fell -0.30 pct, or -2.65 points, to 879.44 points and was up by 8.30 pct year-to-date * The broader Oslo All Share Index was down 0.5 percent * Brent crude futures, a trigger for the oil heavy Oslo Bourse, fell $-1.01 to $74.28 a barrel * Among the biggest firms on the Oslo Bourse, Equinor fell 1.26 pct, Telenor rose 0.
GOGL QEC QTEYF
CALGARY, Alberta, June 04, 2018 (GLOBE NEWSWIRE) -- Questerre Energy Corporation (“Questerre” or the “Company”) (TSX:QEC) (OSE:QEC) reported on the status of legal proceedings related to its assets in Quebec.
2018-05-23 seekingalpha - 2
Razor Energy is an oil-weighted energy producer that has increased its production significantly since 2017 while maintaining a strong balance sheet with leverage being well below 2 times.
BTE PGH CJ CRLFF CPG WCP YGR BNEFF VET SGY ZPTAF RRENF YGRAF RRX QTEYF GXOCF QEC TNEYF GENGF ATU CPG BNE RZREF GXO VET IPOOF GXE BTE SPGYF
CALGARY, Alberta, May 11, 2018 (GLOBE NEWSWIRE) -- Questerre Energy Corporation (“Questerre” or the “Company”) (TSX:QEC) (OSE:QEC) reported today on its financial and operating results for the first quarter ended March 31, 2018.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...